Long road towards effective HER3 targeting in breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Human epidermal growth factor receptor 3 (HER3) drives breast cancer progression and resistance. New HER3-targeted therapies, like antibody-drug conjugates, show promise, highlighting HER3
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Breast cancer is a complex disease with diverse subtypes, necessitating personalized treatment strategies.
- Biomarker identification is crucial for tailoring breast cancer therapies, yet some biomarkers' roles remain unclear.
- Human epidermal growth factor receptor 3 (HER3) is frequently overexpressed in breast cancer and implicated in progression.
Purpose Of The Study
- To review the role of HER3 in breast cancer pathogenesis across all subtypes.
- To explore emerging therapeutic strategies targeting HER3 in breast cancer treatment.
- To evaluate the clinical significance of HER3 detection for guiding breast cancer therapy.
Main Methods
- Comprehensive literature review of studies on HER3 in breast cancer.
- Analysis of HER3's role in cancer progression, metastasis, and drug resistance.
- Examination of recent clinical findings for HER3-targeted therapies, including antibody-drug conjugates.
Main Results
- HER3 overexpression is common in breast cancer (50%-70%) and linked to poorer outcomes.
- HER3 signaling is critical for tumor growth, metastasis, and resistance to various therapies.
- Next-generation antibody-drug conjugates targeting HER3 demonstrate encouraging efficacy in preclinical and clinical studies.
Conclusions
- HER3 is a significant driver of breast cancer progression and a potential therapeutic target.
- Targeting HER3, particularly with advanced antibody-drug conjugates, offers a promising avenue for treatment.
- The clinical utility of HER3 detection warrants further investigation to optimize breast cancer management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...